Intelligence · Clinical Development
Pipeline search results
Programs matching “qing” across our ClinicalTrials.gov index — phase, modality, sponsor, and trial IDs.
Quick answer
Showing 138 pipeline programs matching "qing" from NovaPharmaNews Clinical Development Intelligence — phase, modality, sponsor, and ClinicalTrials.gov trial IDs.
Refine search
Search results
-
CD70 CAR-T cells
Chongqing Precision Biotech Co., Ltd
Metastatic Tumor
4 trials -
CD70 CAR-T cells
Chongqing Precision Biotech Co., Ltd
Ovarian Cancer
1 trial -
CD70-targeted CAR-T cells
Chongqing Precision Biotech Co., Ltd
Renal Cell Carcinoma (RCC)
1 trial -
CEA CAR-T cells
Chongqing Precision Biotech Co., Ltd
Gastric Cancer
1 trial -
CEA CAR-T cells
Chongqing Precision Biotech Co., Ltd
Colorectal Cancer
1 trial -
CEA-targeted CAR-T (Intravenous)
Chongqing Precision Biotech Co., Ltd
NSCLC (Advanced Non-small Cell Lung Cancer)
1 trial -
CEA-targeted CAR-T cells
Chongqing Precision Biotech Co., Ltd
Lung Cancer
1 trial -
CEA-targeted CAR-T cells
Chongqing Precision Biotech Co., Ltd
Colorectal Cancer
1 trial -
CEA-targeted CAR-T cells
Chongqing Precision Biotech Co., Ltd
Peritoneal Metastases From Colorectal Cancer
1 trial -
Cyclophosphamide and Fludarabine
Chongqing Precision Biotech Co., Ltd
Lung Cancer, Nonsmall Cell, Recurrent
1 trial -
GCAR1
Chongqing Precision Biotech Co., Ltd
Sarcoma
1 trial -
HS-IT101 Injection
Qingdao University
Solid Tumor
1 trial -
ICT-121 DC vaccine
Chongqing Precision Biotech Co., Ltd
Glioblastoma Multiforme
1 trial -
Intraperitoneal infusion of FAST CEA-targeted CAR-T
Chongqing Precision Biotech Co., Ltd
Colorectal Cancer
2 trials -
Invivo CAR-T
Chongqing Precision Biotech Co., Ltd
B-Acute Lymphoblastic Leukemia
1 trial -
Irinotecan liposome II combination therapy regimen
Chongqing Claruvis Pharmaceutical Co.,
Non-Muscle Invasive Bladder Urothelial Carcinoma
1 trial -
Jianpi Qinghua granules
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Nonerosive Reflux Disease
1 trial -
MC-1-50
Chongqing Precision Biotech Co., Ltd
Acute Lymphoblastic Leukemia, in Relapse
1 trial -
MC-1-50
Chongqing Precision Biotech Co., Ltd
Systemic Lupus Erythematosus (SLE)
1 trial -
MC-1-50
Chongqing Precision Biotech Co., Ltd
B Cell Lymphoma
1 trial -
NTQ5082 capsule
Nanjing Chia-tai Tianqing Pharmaceutical
Complement-mediated Hemolytic Diseases
1 trial -
NY-ESO-1（TCR Affinity Enhancing Specific T cell Therapy）
Chongqing Precision Biotech Co., Ltd
Bone Sarcoma
1 trial -
OKN4395
Chongqing Precision Biotech Co., Ltd
Solid Tumours
1 trial -
PB-2018-V12
Chongqing Precision Biotech Co., Ltd
Non-small Cell Lung Cancer
1 trial
Frequently asked questions
What is the Clinical Development Intelligence Platform?
It is NovaPharmaNews pipeline intelligence hub covering 20,548 clinical development programs — not just a directory. It includes phase distribution dashboards, therapeutic area overviews, NDA/BLA watchlists, upcoming readouts, company pipeline rankings, competitive landscape maps, and personalized watchlists.
How does this compare to Evaluate Pharma or Citeline?
Like Evaluate Pharma and Citeline Trialtrove, we index ClinicalTrials.gov programs by sponsor, phase, and indication. Our platform adds cross-links to NovaPharmaNews company profiles, drug INN pages, patents, and congress readout calendars — improving crawl depth and reducing orphan program pages.
Where does pipeline data come from?
Program records derive from ClinicalTrials.gov and link to sponsor company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment decisions. See our data sources page for attribution.
Can I follow a company or program for updates?
Yes — use the watchlist forms on this page to follow sponsors, individual programs, disease clusters, or therapeutic areas. Alerts use the same subscription infrastructure as our events intelligence hub.